Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
Identifieur interne : 000280 ( PascalFrancis/Curation ); précédent : 000279; suivant : 000281Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
Auteurs : Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias [Canada] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner H. Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni]Source :
- Annals of neurology [ 0364-5134 ] ; 2003.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Cartographie, Homme.
English descriptors
- KwdEn :
Abstract
Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective in Parkinson's disease (PD), and a pilot clinical study using 18F-dopa positron emission tomography (PET) suggested a slower loss of striatal dopamine storage with ropinirole compared with levodopa. This prospective, 2-year, randomized, double-blind, multinational study compared the rates of loss of dopamine-terminal function in de novo patients with clinical and 18F-dopa PET evidence of early PD, randomized 1 to 1 to receive either ropinirole or levodopa. The primary outcome measure was reduction in putamen 18F-dopa uptake (Ki) between baseline and 2-year PET. Of 186, 162 randomized patients were eligible for analysis. A blinded, central, region-of-interest analysis showed a significantly lower reduction (p = 0.022) in putamen Ki over 2 years with ropinirole (-13.4%; n = 68) compared with levodopa (-20.3%; n = 59; 95% confidence interval [CI], 0.65-13.06). Statistical parametric mapping localized lesser reductions in 18F-dopa uptake in the putamen and substantia nigra with ropinirole. The greatest Ki decrease in each group was in the putamen (ropinirole, -14.1%; levodopa, -22.9%; 95% CI, 4.24-13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by 18F-dopa PET.
pA |
|
---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A43
Links to Exploration step
Pascal:03-0498653Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study</title>
<author><name sortKey="Whone, Alan L" sort="Whone, Alan L" uniqKey="Whone A" first="Alan L." last="Whone">Alan L. Whone</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Emory University School of Medicine</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Davis, Margaret" sort="Davis, Margaret" uniqKey="Davis M" first="Margaret" last="Davis">Margaret Davis</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Emory University School of Medicine</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Reske, Sven" sort="Reske, Sven" uniqKey="Reske S" first="Sven" last="Reske">Sven Reske</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Universität Ulm</s1>
<s2>Ulm</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Nahmias, Claude" sort="Nahmias, Claude" uniqKey="Nahmias C" first="Claude" last="Nahmias">Claude Nahmias</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>McMaster University</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Division of Neurology, Department of Medicine, University of Toronto</s1>
<s2>Ontario, Canada</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre, INSERM U455, Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Ribeiro, Maria J" sort="Ribeiro, Maria J" uniqKey="Ribeiro M" first="Maria J." last="Ribeiro">Maria J. Ribeiro</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>CFA-CNRS URA 2210, Service Hospitalier F. Joliot</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Remy, Philippe" sort="Remy, Philippe" uniqKey="Remy P" first="Philippe" last="Remy">Philippe Remy</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>CFA-CNRS URA 2210, Service Hospitalier F. Joliot</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner H" sort="Poewe, Werner H" uniqKey="Poewe W" first="Werner H." last="Poewe">Werner H. Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Clinical Neurology, University of Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>University of South Florida and Tampa General Healthcare</s1>
<s2>Tampa, FL</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0498653</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0498653 INIST</idno>
<idno type="RBID">Pascal:03-0498653</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A43</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000280</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study</title>
<author><name sortKey="Whone, Alan L" sort="Whone, Alan L" uniqKey="Whone A" first="Alan L." last="Whone">Alan L. Whone</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Emory University School of Medicine</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Davis, Margaret" sort="Davis, Margaret" uniqKey="Davis M" first="Margaret" last="Davis">Margaret Davis</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Emory University School of Medicine</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Reske, Sven" sort="Reske, Sven" uniqKey="Reske S" first="Sven" last="Reske">Sven Reske</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Universität Ulm</s1>
<s2>Ulm</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Nahmias, Claude" sort="Nahmias, Claude" uniqKey="Nahmias C" first="Claude" last="Nahmias">Claude Nahmias</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>McMaster University</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Division of Neurology, Department of Medicine, University of Toronto</s1>
<s2>Ontario, Canada</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre, INSERM U455, Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Ribeiro, Maria J" sort="Ribeiro, Maria J" uniqKey="Ribeiro M" first="Maria J." last="Ribeiro">Maria J. Ribeiro</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>CFA-CNRS URA 2210, Service Hospitalier F. Joliot</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Remy, Philippe" sort="Remy, Philippe" uniqKey="Remy P" first="Philippe" last="Remy">Philippe Remy</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>CFA-CNRS URA 2210, Service Hospitalier F. Joliot</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner H" sort="Poewe, Werner H" uniqKey="Poewe W" first="Werner H." last="Poewe">Werner H. Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Clinical Neurology, University of Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>University of South Florida and Tampa General Healthcare</s1>
<s2>Tampa, FL</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Aminoacid</term>
<term>Cartography</term>
<term>Catecholamine</term>
<term>Comparative study</term>
<term>D2 Dopamine receptor</term>
<term>Dopa</term>
<term>Dopamine</term>
<term>Dopamine agonist</term>
<term>Double blind study</term>
<term>Emission tomography</term>
<term>Human</term>
<term>Levodopa</term>
<term>Parkinson disease</term>
<term>Positron</term>
<term>Prognosis</term>
<term>Putamen</term>
<term>Ropinirole</term>
<term>Uptake</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Ropinirole</term>
<term>Tomoscintigraphie</term>
<term>Dopa</term>
<term>Dopamine</term>
<term>Putamen</term>
<term>Cartographie</term>
<term>Etude comparative</term>
<term>Lévodopa</term>
<term>Positon</term>
<term>Stimulant dopaminergique</term>
<term>Etude double insu</term>
<term>Homme</term>
<term>Pronostic</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique D2</term>
<term>Aminoacide</term>
<term>Catécholamine</term>
<term>Captation</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Cartographie</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective in Parkinson's disease (PD), and a pilot clinical study using <sup>18</sup>
F-dopa positron emission tomography (PET) suggested a slower loss of striatal dopamine storage with ropinirole compared with levodopa. This prospective, 2-year, randomized, double-blind, multinational study compared the rates of loss of dopamine-terminal function in de novo patients with clinical and <sup>18</sup>
F-dopa PET evidence of early PD, randomized 1 to 1 to receive either ropinirole or levodopa. The primary outcome measure was reduction in putamen <sup>18</sup>
F-dopa uptake (Ki) between baseline and 2-year PET. Of 186, 162 randomized patients were eligible for analysis. A blinded, central, region-of-interest analysis showed a significantly lower reduction (p = 0.022) in putamen Ki over 2 years with ropinirole (-13.4%; n = 68) compared with levodopa (-20.3%; n = 59; 95% confidence interval [CI], 0.65-13.06). Statistical parametric mapping localized lesser reductions in <sup>18</sup>
F-dopa uptake in the putamen and substantia nigra with ropinirole. The greatest Ki decrease in each group was in the putamen (ropinirole, -14.1%; levodopa, -22.9%; 95% CI, 4.24-13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by <sup>18</sup>
F-dopa PET.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0364-5134</s0>
</fA01>
<fA02 i1="01"><s0>ANNED3</s0>
</fA02>
<fA03 i2="1"><s0>Ann. neurol.</s0>
</fA03>
<fA05><s2>54</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>WHONE (Alan L.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>WATTS (Ray L.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>STOESSL (A. Jon)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DAVIS (Margaret)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>RESKE (Sven)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>NAHMIAS (Claude)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LANG (Anthony E.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>RASCOL (Olivier)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>RIBEIRO (Maria J.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>REMY (Philippe)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>POEWE (Werner H.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>HAUSER (Robert A.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>BROOKS (David J.)</s1>
</fA11>
<fA14 i1="01"><s1>Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, Emory University School of Medicine</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Universität Ulm</s1>
<s2>Ulm</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>McMaster University</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Division of Neurology, Department of Medicine, University of Toronto</s1>
<s2>Ontario, Canada</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre, INSERM U455, Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>CFA-CNRS URA 2210, Service Hospitalier F. Joliot</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Department of Clinical Neurology, University of Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>University of South Florida and Tampa General Healthcare</s1>
<s2>Tampa, FL</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>REAL-PET Study Group</s1>
<s3>INC</s3>
</fA17>
<fA20><s1>93-101</s1>
</fA20>
<fA21><s1>2003</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16555</s2>
<s5>354000119867680110</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2003 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>30 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>03-0498653</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Annals of neurology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective in Parkinson's disease (PD), and a pilot clinical study using <sup>18</sup>
F-dopa positron emission tomography (PET) suggested a slower loss of striatal dopamine storage with ropinirole compared with levodopa. This prospective, 2-year, randomized, double-blind, multinational study compared the rates of loss of dopamine-terminal function in de novo patients with clinical and <sup>18</sup>
F-dopa PET evidence of early PD, randomized 1 to 1 to receive either ropinirole or levodopa. The primary outcome measure was reduction in putamen <sup>18</sup>
F-dopa uptake (Ki) between baseline and 2-year PET. Of 186, 162 randomized patients were eligible for analysis. A blinded, central, region-of-interest analysis showed a significantly lower reduction (p = 0.022) in putamen Ki over 2 years with ropinirole (-13.4%; n = 68) compared with levodopa (-20.3%; n = 59; 95% confidence interval [CI], 0.65-13.06). Statistical parametric mapping localized lesser reductions in <sup>18</sup>
F-dopa uptake in the putamen and substantia nigra with ropinirole. The greatest Ki decrease in each group was in the putamen (ropinirole, -14.1%; levodopa, -22.9%; 95% CI, 4.24-13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by <sup>18</sup>
F-dopa PET.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Ropinirol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Tomoscintigraphie</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Emission tomography</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tomocentelleografía</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Dopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Dopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Putamen</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Putamen</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Putamen</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Cartographie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Cartography</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Cartografía</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Positon</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Positron</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Positrón</s0>
<s5>19</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>21</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>21</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>21</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Etude double insu</s0>
<s5>22</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Double blind study</s0>
<s5>22</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Estudio doble ciego</s0>
<s5>22</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Homme</s0>
<s5>23</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Human</s0>
<s5>23</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Hombre</s0>
<s5>23</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>24</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>24</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>24</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>25</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Agonist</s0>
<s5>25</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Agonista</s0>
<s5>25</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0>
<s5>26</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0>
<s5>26</s5>
<s6>«D2» Dopamine receptor</s6>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0>
<s5>26</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Aminoacide</s0>
<s5>27</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Aminoacid</s0>
<s5>27</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Aminoácido</s0>
<s5>27</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>28</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>28</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>28</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE"><s0>Captation</s0>
<s5>35</s5>
</fC03>
<fC03 i1="19" i2="X" l="ENG"><s0>Uptake</s0>
<s5>35</s5>
</fC03>
<fC03 i1="19" i2="X" l="SPA"><s0>Captación</s0>
<s5>35</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>41</s5>
</fC07>
<fN21><s1>335</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000280 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000280 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= PascalFrancis |étape= Curation |type= RBID |clé= Pascal:03-0498653 |texte= Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study }}
This area was generated with Dilib version V0.6.29. |